Case report

Vocal cord paralysis in Charcot–Marie–Tooth type 4b1 disease associated with a novel mutation in the myotubularin-related protein 2 gene: A case report and review of the literature

Alberto Andrea Zambon a,⁎, Maria Grazia Natali Sora a, Giovanna Cantarella b, Federica Cerri a,Angelo Quattrini ac, Giancarlo Comi a, Stefano Carlo Previtali ad, Alessandra Bolino e

a Department of Neurology, San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy
b Otolaryngology Department, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, Milan, Italy
c Experimental Neuropathology Unit, INSPE and Division of Neuroscience, San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy
d Neuromuscular Repair Unit, INSPE and Division of Neuroscience, San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy
e Human Inherited Neuropathies Unit, INSPE and Division of Neuroscience, San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy

Received 14 September 2016; received in revised form 21 November 2016; accepted 9 January 2017

Abstract

Charcot–Marie–Tooth neuropathy (CMT) represents a widely heterogeneous group of disorders with a broad spectrum of clinical and electrophysiological features. More than 80 genes have been identified so far as responsible for CMT, including dominant, recessive and X-linked forms [1].

CMT type 4B1 (CMT4B1) is an autosomal recessive (AR) motor and sensory demyelinating neuropathy characterized by the association of early-onset neurological symptoms and typical histological findings. The histopathological hallmark is the presence of myelin outfoldings in the nerve, redundant and irregular loops of myelin around the axon [2]. The disease is caused by loss-of-function mutations in the Myotubularin-related 2 gene (MTMR2) on chromosome 11q22 [3].

To date, few cases have been reported and further clarification of the different phenotypes associated with this gene is needed, particularly in consideration of the poor knowledge on the natural history of the disease and its severe course, which may need to provide clinical warnings to care-givers.

We here report the case of a patient with a novel mutation in the MTMR2 gene, who started to experience stridor and was diagnosed with bilateral vocal cord paralysis at the age of 18 months.

1. Introduction

Charcot–Marie–Tooth neuropathy (CMT) represents a widely heterogeneous group of disorders with a broad spectrum of clinical and electrophysiological features. More than 80 genes have been identified so far as responsible for CMT, including dominant, recessive and X-linked forms [1].

CMT type 4B1 (CMT4B1) is an autosomal recessive (AR) motor and sensory demyelinating neuropathy characterized by the association of early-onset neurological symptoms and typical biopsy findings. The histopathological hallmark is the presence of myelin outfoldings in the nerve, redundant and irregular loops of myelin around the axon [2]. The disease is caused by loss-of-function mutations in the Myotubularin-related 2 gene (MTMR2) on chromosome 11q22 [3].

Keywords: CMT4B1; MTMR2; Vocal cord palsy; Autosomal recessive neuropathy; Vocal fold laterofixation

http://dx.doi.org/10.1016/j.nmd.2017.01.006
0960-8966/© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
and died at age of 9 years of respiratory failure, while still ambulant [Pedigree is reported in Fig. 1].

Our patient underwent orthopedic assessment at the age of 12 months and was then evaluated by a neurologist at 18 months. Neurological examination revealed bilateral facial weakness, reduced limb tone, muscle wasting prevalent in lower limbs, absence of tendon reflexes, proximal and distal weakness prevalent in lower limbs, hoarseness and inspiratory stridor. No palpable nerves were noted. Electrophysiological studies performed at 25 months revealed severe motor-sensory demyelinating neuropathy with secondary axonal loss [Ulnar nerve motor conduction velocity (CV) 27.1 m/s, CMAP 2 mV; Peroneal nerve motor CV 17.3 m/s, CMAP 0.4 mV; Median nerve sensory CV 19.4 m/s, SAP 2.8 μV; Sural nerve SAP not evocable].

In the following months neurological symptoms did not significantly evolve but the patient continued to present labored respiration with mild stridor. In January 2015 she underwent examination of the larynx by flexible videolaryngoscopy. The exam revealed left vocal cord palsy with right-sided hypomobility. Due to potential complication related to vocal cord paralysis, including respiratory insufficiency with possible aspiration and bronchopneumonia, the patient was considered a candidate for tracheostomy. However, considering the lack of progression of laryngeal symptoms in the following year and the presence of a normal polysomnography performed at 32 months [Oxygen desaturation events index (n°/h): 0.8. Minimum SatO2% value: 90, Mean SatO2% value: 94], surgical intervention was not performed and a regular follow-up was scheduled. Her laryngeal motility disorder was monitored by

Fig. 1. Molecular analysis and nerve biopsy. (a) Pedigree of the reported family with two affected individuals, first cousins. (b) Electropherograms of exon 6 of the MTMR2 gene show that the c.484 C>T (p.Arg162*) mutation is present in heterozygosity in the unaffected parents and in homozygosity in the proband (IV, 5). The asterisk in the electropherograms indicates the mutation. (c) Sural nerve biopsy of the proband revealed the presence of fibers with outfoldings, infoldings and with redundant basal lamina (arrow). Bar is 1 μm.
flexible videolaryngoscopies performed at intervals of 3–4 months. A progressive respiratory deterioration was observed with constant stridor for every minimal effort, activation of accessory respiratory muscles and inspiratory chest retractions, restlessness and difficulties during feeding. At the age of 3 years and 4 months a complete bilateral laryngeal paralysis was observed, with vocal cords in adduction and a respiratory space of about 1 mm. The parents refused surgical treatment at that time. At the age of 3 years and 7 months, due to worsening of clinical symptoms after an upper airway infection with severe respiratory obstruction, the patient required treatment in the Intensive Care Unit. Before admission the child was still able to walk unassisted with bilateral foot-drop and in the previous weeks she had started to present occasional dysphagia for both liquid and solid food. Muscle strength measured by MRC was 3–4 proximally in upper and lower limbs, 1–2 in the anterior tibialis and peroneus muscles. First, we performed glottic enlargement by direct microlaryngoscopy as an attempt to avoid permanent tracheotomy. After deep sedation, the vocal cords widely opened suggesting that the activity of vocal cords adductor muscles was a possible co-factor of the severe glottic obstruction. After incision of the mucosal surface of the posterior right vocal cord by CO2 laser, we partially vaporized the vocal muscle. Then, we placed two endo-extralaryngeal sutures by Lichtenberger needle carrier [4] in order to achieve lateralization of the posterior third of the vocal cord and to obtain closure of the cordotomy wound. We obtained the widening of the glottic space and extubated the child, who showed progressive respiratory improvement. A week after first surgery, the patient underwent tracheotomy as stridor had fully recurred and severe respiratory effort was persisting. Videolaryngoscopy showed the recurrence of glottic obstruction due to active adduction of the arytenoids during the whole respiratory cycle. After tracheotomy the child showed a general health improvement and resumed oral feeding.

2.2. Nerve biopsy and molecular findings

Sequencing analysis was initially performed in the GDAP1 gene, responsible for autosomal recessive CMT4A and frequently associated with vocal cord paresis and stridor. As no mutations were detected, sural nerve biopsy was carried out at 20 months of age. Morphological analysis revealed reduced fiber number, several fibers with reduced myelin thickness, rare onion bulbs and the presence of abundant myelin outfoldings (Fig. 1), which are a hallmark of CMT4B neuropathy. Given the early onset of the neuropathy, MTMR2 was first analyzed by performing Sanger sequencing analysis and a novel nonsense mutation in exon 6c.484 C>T; p.Arg162* was found. Consistent with an autosomal recessive inheritance, this mutation was present in homozygosity in the proband whereas unaffected parents were both heterozygous carriers of the mutation. This variant was not reported in the SNP database (dbSNP build 132, http://www.ncbi.nlm.nih.gov/projects/SNP) or in 1000 Genomes (www.1000genomes.org). The premature truncation of the MTMR2 protein at codon 162 leads to the deletion of part of the RID domain, the entire PTP-like phosphatase domain and the CC (coiled-coil) C-terminal motif [5,6]. Moreover, mutations in the MTMR13 gene responsible for CMT4B2, a severe early onset demyelinating neuropathy also characterized by myelin outfoldings in the nerve, were excluded in the proband as well.

3. Discussion

ARCMTs are usually associated with more severe phenotypes as compared to dominant forms [7]. Along with motor and sensory defects, they usually present earlier onset and more marked distal limb deformities, sometimes associated with major spinal abnormalities and other complications. Among CMT-associated complications, vocal cord paralysis is still an underestimated finding. Vocal cord paralysis has been reported as an early, severe and frequent symptom of GDAP1-associated neuropathy [CMT4A], often followed by diaphragmatic dysfunction [8–13], and in both AD and AR forms of CMT2A (mutations in the MFN2 gene) [14,15]. Few cases are reported in axonal dominant CMT2C (mutations in the transient receptor potential cation channel, subfamily V, member 4; TRPV4) [16–18] and as a later involvement in a patient harboring a dominant heterozygous mutation of early growth response 2 (EGR2) gene [19]. Rarely, it has been associated with other variants and polymorphisms [20–24].

An overview of all previously reported cases with early onset in life is provided in Table 1.

Regarding CMT4B1, vocal cord paralysis was reported in one Italian patient, one English patient, and three Algerian siblings by Sabatelli [25], Tyson and Houlden [26,27] and Nouioua [28], respectively. All of the patients suffered from early-onset (1–2 years-old) severe demyelinating neuropathy associated with respiratory difficulties. The Algerian siblings presented prominent chest deformities possibly secondary to breathing impairment. In the latter cases sequencing analysis revealed mutations located in exon 4 (c.G308A; p.Gly103Glu and c.331dupA; p.Arg111LysfsX24, respectively). Notably, laryngeal involvement was present in early stages of the disease in all cases.

In our patient, vocal cord paralysis presented as an early symptom, as the onset was between 1 and 2 years of age. The vocal cord disease manifested as a hoarse voice and stridor, associated with the use of accessory inspiratory muscles. An asymmetric involvement of vocal cords was initially noticed with a more severe paralysis of the left cord. This finding was present in previous reports [8,20] and it has been interpreted as a sign of length-dependent degeneration of the neuropathy. However, initial paralysis of the right vocal cord is reported as well and usually a progression toward bilateral deficit is observed. Most of the genes involved in vocal cord paralysis encode for proteins playing a role also in neurons. We may speculate that vocal cord paralysis results from neuronal dysfunction in the bulbar nucleus of the recurrent nerve, rather than a consequence of a length-dependent neuropathy. This might also explain why only few CMT subtypes develop this complication and why no clear correlation with the severity of neuropathy is observed.

To our knowledge, no progression to respiratory failure was seen in previously reported cases. The patient reported by Tyson...
Table 1
Clinical reports of CMT cases associated with laryngeal involvement in the first 2 decades.

| Reference | Gender/number of patients (age) | Country of origin | Age of walking (months) | Age of onset (months) | Age of VF involvement (months) | Cranial nerve involvement | Other peculiar features | Loss of ambulation (age) | Gene | CMT type, mode of inheritance |
|-----------|--------------------------------|-------------------|-------------------------|----------------------|-------------------------------|--------------------------|-------------------------|------------------------|------|-----------------------------|
| Present case | F/1 (3y) | Pakistan | 16 | 12–18m | 18m | Bilateral facial paresis, mild dysphagia | Pes planus | Still walking | MTMR2 | CMT4B1, AR |
| Sabatelli et al., 1994 | F/1 (28y) | Italy | 13 | 14–15m | 15m | Dysphagia, weakness of masticatory muscles, facial paresis | NA | 22y | MTMR2 | CMT4B1, AR |
| Luigetti et al., 2013 | M/1 (16y) | England | 13 | 13–36m | 36m | Difficulty with phonation, chewing, swallowing | Diaphragm paresis | 16y | MTMR2 | CMT4B1, AR |
| Tyson et al., 1997 | M/1 (13y) | Wales | NA | 1–10y | 1–10y | Stridor present at onset | Facial paresis | NA | NA | NA |
| Nouioua et al., 2011 | M/3 (8-16y) | Algeria | NA | 1–2y | | NA | Chest deformities +++ Breathing difficulties. Pes equinovarus, claw hands | Still walking | MTMR2 | CMT4B1, AR |
| Dyck et al., 1994 | M/1 (34y) | Japan; Costa Rica | 15 | 36 | 2y, 6m | NA | Facial paresis; dysphagia | NA | NA | GDAP1 | CMT4A, AR |
| Sevilla et al., 2003 | F/1 (34y); M/1 (64y) | France | 12–18 | Birth–2y | late | NA | NA | 9y; 12y; 30y | GDAP1 | CMT4A, AR |
| Azeddine et al., 2003 | M/1 (30y) | Morocco | Normal | 3y | 20y | NA | NA | 15y | GDAP1 | CMT4A, AR |
| Stojkovic et al., 2004 | F/2 (32-33y) | France | 20 | <2 y | early in life | NA | Paralysis of one hemicranial nerve palsy | NA | 25y | GDAP1 | CMT4A, AR |
| Sevilla et al, 2008 | F/3 (16-49y) | Spain | 12–18 | <1y–8y | NA | Bilateral facial weakness (n° 1); dysphagia (n° 1) | Diaphragm paresis | 9–38y (median 16) | GDAP1 | CMT4A, AR |
| Moroni et al., 2009 | M/1 (16y); F/1 (11y) | Italy | 12–18 | 2y | 13y | NA | NA | 12y; still walking | GDAP1 | CMT4A, AR |
| MeEntagart et al., 2001 [30] | M/13; F/8 | Wales | NA | 2nd decade | 2nd decade | NA | Distal muscular atrophy | NA | Dynactin | dHMN-VII, AD |
| Polke et al., 2011 | F/1 (39y) | Italy | NA | 3y | NA | Severe facial weakness, hearing loss, visual loss | Severe difficulty, respiratory muscles weakness | Wheelchair (age not known) | MFN2 | CMT2, AR |
| Bombelli et al., 2014 | 6 | NA | NA | Early onset | NA | NA | Severe disability (5/6) | NA | MFN2 | CMT2, AD |
| Pehlivan et al., 2015 [31] | M/1 (♀ 33 m) | Turkey | Not acquired | <6m | <6m | NA | Lateral knee contractures, hammer toes, pes equinus and pes cavus | NA | TRIM2 | AR |

Abbreviations: AD, autosomal dominant; AR, autosomal recessive; CMT, Charcot–Marie–Tooth; CSMAA, congenital spinal muscular atrophy and arthrogryposis; dHMN, distal hereditary motor neuropathy; F, female; GDAP1, ganglioside-induced differentiation-associated protein 1; m, months; M, male; MFN2, mitofusin-2; MTMR2, myotubularin related protein 2; NA: data not available; SPSMA, scapula-peroneal spinal muscular atrophy; TRIM2, tripartite motif containing 2; TRPV4, transient receptor potential cation channel subfamily V member 4; VF, vocal fold; y, years; †, died.

and colleagues, when aged 16, began to develop frequent chest infections and nocturnal hypventilation. He was started on a nighttime BIPAP facial mask ventilator with resolution of symptoms. Nevertheless, as shown by our proposita, progressive laryngeal involvement may cause life-threatening airway obstruction, aspiration and pneumonia. Decreased life expectancy and premature death, which was previously described in other forms of CMT [5,8], was observed also in our patient’s first cousin, who was likely to harbor the same gene mutation (see genetic pedigree) and died of sudden death due to upper airway involvement at the age of 9, while he was still able to walk unaided.

In conclusion, we suggest that the finding of bilateral laryngeal paralysis or hypomotility due to unknown causes should prompt a warning for a neuromuscular disorder, notably a hereditary neuropathy, and help the physician to target molecular investigations. Particularly, we feel that laryngeal involvement might be a relevant and initial finding in
early-onset CMT4B1 neuropathy and thus all the patients with positive molecular genetics for MTMR2 should be promptly investigated for laryngeal function. Periodic videolaryngoscopy follow-up is mandatory in patients with a CMT subtype associated with vocal cord paralysis in order to detect possible vocal cord hypomotility and to quantify the degree of airway obstruction. It is known that a young child can tolerate without symptoms a laryngotracheal obstruction up to 70% of the lumen, and that a slowly progressing obstruction may manifest with moderate stridor up to 80% or more [29]. Nevertheless, in such a clinical condition even a mild upper airway infection might have lethal consequences. Severe chest retractions, failure to thrive, refusal of food and no interest in playing might all be the signs of a critical condition which might rapidly precipitate [29]. Parents of the child should be made aware of their child condition in order to seek for hospital assistance as soon as they notice worsening of respiratory distress. In the described case, a first attempt to achieve a wider glottic space was performed by a vocal cord lateralization procedure; this is a conservative mean of widening the posterior glottis respecting both phanotary and sphincteric functions of the larynx. Nevertheless, this procedure did not work in our patient, possibly due to the neuropathy as pathogenic mechanism of the vocal cord paralysis. Moreover, this case showed the role of active contraction of vocal cord adductor muscles as a cause of laryngeal obstruction in CMT patients. Tracheotomy appears then to be a necessary procedure to relieve the respiratory distress in patients affected by bilateral laryngeal paralysis in CMT.

Acknowledgments

A.B. was supported by Telethon Foundation-Italy (GGP12017 and GGP15012A), S.C.P. by Telethon-Italy (GUP13006, GGP12024, GGP15012B); AFM-Telethon 18518; the Italian Ministry of Health (RF-2011-02347127) and CoFin Regione Lombardia n. 96.

References

[1] Gutmann L, Shy M. Update on Charcot-Marie-Tooth disease. Curr Opin Neurol 2015;28:462–7.
[2] Ohtsuki A, Murai Y, Ikueda M, Fujita T, Furuya H, Kuroiwa Y. Autosomal recessive motor and sensory neuropathy with excessive myelin outfolding. Muscle Nerve 1989;12:568–75.
[3] Bolino A, Muglia M, Conforti FL, et al. Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding myotubulin-related protein-2. Nat Genet 2000;25:17–19.
[4] Lichtenberger G. Reversible immediate and definitive lateralization of paralyzed vocal cords. Eur Arch Otorhinolaryngol 1999;256:407–11.
[5] Luigetti M, Bolino A, Scarlino S, Sabatelli M. A novel homozygous mutation in the MTMR2 gene in two siblings with ‘hypermyelinating neuropathy’. J Peripher Nerv Syst 2013;18:192–4.
[6] Hnia K, Vaccari I, Bolino A, Laporte J. Myotubulin phosphoinositide phosphatases: cellular functions and disease pathophysiology. Trends Mol Med 2012;18:317–27.
[7] Tazir M, Bellatache M, Nourioua S, Vallat JM. Autosomal recessive Charcot-Marie-Tooth disease: from genes to phenotypes. J Peripher Nerv Syst 2013;18:113–29.
[8] Sevilla T, Jaijo T, Naufal D, et al. Vocal cord paresis and diaphragmatic dysfunction are severe and frequent symptoms of GDAP1-associated neuropathy. Brain 2008;131:3051–61.
[9] Sevilla T, Cuesta A, Chumillas MJ, et al. Clinical, electrophysiological and morphological findings of Charcot-Marie-Tooth neuropathy with vocal cord palsy and mutations in the GDAP1 gene. Brain 2003;126:2023–33.
[10] Stojkovic T, Latour P, Viet G, et al. Vocal cord and diaphragm paralysis, as clinical features of a French family with autosomal recessive Charcot-Marie-Tooth disease, associated with a new mutation in the GDAP1 gene. Neuromusc Disord 2004;14:261–4.
[11] Azeddine H, Ruberg M, Ente D, et al. Variability of disease progression in a family with autosomal recessive CMT associated with a S194X and new R310Q mutation in the GDAP1 gene. Neuromusc Disord 2003;13:341–6.
[12] Moroni I, Morbin M, Milani M, et al. Novel mutations in the GDAP1 gene in patients affected with early-onset axonal Charcot-Marie-Tooth type 4A. Neuromusc Disord 2009;19:476–80.
[13] Boerkoel CF, Takashima H, Nakagawa M, et al. CMT4A: identification of a Hispanic GDAP1 founder mutation. Ann Neurol 2003;53:400–5.
[14] Polke JM, Laura M, Paresyon D, et al. Recessive axonal Charcot-Marie-Tooth disease due to compound heterozygous mitofusin 2 mutations. Neurology 2011;77:168–73.
[15] Bombelli F, Stojkovic T, Dubourg O, et al. Charcot-Marie-Tooth disease type 2A: from typical to rare phenotypic and genotypic features. JAMA Neurol 2014;71:1036–42.
[16] Chen DH, Sul Y, Weiss M, et al. CMT2C with vocal cord paresis associated with short stature and mutations in the TRPV4 gene. Neurology 2010;75:1968–75.
[17] Dyck PJ, Litchy WJ, Minnereit S, et al. Hereditary motor and sensory neuropathy with diaphragm and vocal cord paresis. Ann Neurol 1994;35:608–15.
[18] Echaniz-Laguna A, Dubourg O, Carlier P, et al. Phenotypic spectrum and incidence of TRPV4 mutations in patients with inherited axonal neuropathy. Neurology 2014;82:1919–26.
[19] Paresyon D, Taroni F, Botti S, et al. Cranial nerve involvement in CMT disease type 1 due to early growth response 2 gene mutation. Neurology 2000;54:1696–8.
[20] Benson B, Sulica L, Guss J, Blitzer A. Laryngeal neuropathy of Charcot-Marie-Tooth disease: further observations and novel mutations associated with vocal fold paresis. Laryngoscope 2010;120:291–6.
[21] Thomas PK, Marques W Jr, Davis MB, et al. The phenotypic manifestations of chromosome 17p11.2 duplication. Brain 1997;120(Pt 3):465–78.
[22] Sulica L, Blitzer A, Lovelace RE, Kaufmann P. Vocal fold paresis of Charcot-Marie-Tooth disease. Ann Otol Rhinol Laryngol 2001;110:1072–6.
[23] Hwang SH, Kim EJ, Hong YB, et al. Distal hereditary motor neuropathy type 7B with Dynamin 1 mutation. Mol Med Rep 2016;14:3362–8.
[24] Fonkem E, Skordilis MA, Binkley EM, et al. Ethambutol toxicity exacerbating the phenotype of CMT2A2. Muscle Nerve 2013;48:140–4.
[25] Babatelli M, Migugno T, Lippi G, et al. Autosomal recessive hypermyelinating neuropathy. Acta Neuropathol 1994;87:337–42.
[26] Tyson J, Ellis D, Fairbrother U, et al. Hereditary demyelinating neuropathy of infancy. A genetically complex syndrome. Brain 1997;120:47–63.
[27] Houlden H, King RH, Wood NW, Thomas PK, Reilly MM. Mutations in the 5′ region of the myotubulin-related protein 2 (MTMR2) gene in autosomal recessive hereditary neuropathy with focally folded myelin. Brain 2001;124:907–15.
[28] Nouioua S, Hamadouche T, Funalot B, et al. Novel mutations in the PRX and the MTMR2 genes are responsible for unusual Charcot-Marie-Tooth disease phenotypes. Neuromusc Disord 2011;21:543–50.
[29] Monnier P. Clinical evaluation of airway obstruction. In: Pediatric airway surgery. Springer Berlin Heidelberg; 2011. p. 31–44.
[30] McIntagart M, Norton N, Williams H, et al. Localization of the gene for distal hereditary motor neuropathy VII (dHMN-VII) to chromosome 2q14. Am J Hum Genet 2001;68:1270–6.
[31] Pehlivan D, Coban Akdemir Z, Karaca E, et al. Exome sequencing reveals homozgyous TRIM24 mutation in a patient with early onset CMT and bilateral vocal cord paralysis. Hum Genet 2015;134:671–3.